STUDY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE ENZYME AND ISOPROSTANE ON PREECLAMPSIA WITH NIFEDIPINE, METHYLDOPA, AND MAGNESIUM SULFATE THERAPY by LUKITASARI, LINA et al.
International Journal of Applied Pharmaceutics
ISSN - 0975 - 7058 Vol 11, Special Issue 5, 2019
STUDY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE ENZYME AND ISOPROSTANE ON 
PREECLAMPSIA WITH NIFEDIPINE, METHYLDOPA, AND MAGNESIUM SULFATE THERAPY
LINA LUKITASARI1*, ADITIAWARMAN ADITIAWARMAN2, MASYHUDI MASYHUDI3, SITI KHAERUNNISA1, 
SUHARTATI SUHARTATI4
1Department of Medical Biochemistry, Faculty of Medicine, Airlangga University, Indonesia. 2Department of Obstetrics and 
Gynecology, Faculty of Medicine, Airlangga University, Dr. Soetomo Hospital, Indonesia. 3Department of Obstetrics and Gynecology, 
Muhamad Soewandi Hospital, Surabaya. 4Department of Medical Biochemistry, Wijaya Kusuma Surabaya University, Indonesia. 
Email: lina-l@fk.unair.ac.id
Received:  28 January 2019, Revised and Accepted: 29 July 2019
ABSTRACT
Objective: The objective of this research is to measure erythrocyte glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and isoprostane and 
to correlate enzyme activity of G6PD with proteinuria and isoprostane in pregnant with proteinuria after the administration of nifedipine, methyldopa, 
and magnesium sulfate.
Methods: This cross-sectional study was held in Soewandi Hospital, Surabaya, East Java, Indonesia. This study used total sampling as much as 30 
pregnant women with proteinuria who got nifedipine, methyldopa, and magnesium sulfate administration, age ranged from 17 to 48 years during their 
third trimester (>20 weeks). G6PD enzyme activity was measured from plasma by spectrophotometric method; plasma isoprostane was measured 
by competitive-ELISA method; and proteinuria urine spot was analyzed by urine dipstick from standardized laboratory of the hospital. Statistical 
analysis used in this study was Spearman’s correlation coefficient.
Results: In this research, the effect of proteinuria +1 (OR=0.056) is lower than proteinuria +3 level on the presence of high G6PD enzyme activity, 
and proteinuria +2 (OR=0.933) is lower than proteinuria +3 level on the presence of high G6PD enzyme activity in pregnant women with proteinuria. 
G6PD enzyme was positively correlated (p=0.08) with proteinuria, and the connection was statistically significant. There was no significant statistic 
correlation between G6PD enzyme activity and isoprostane concentration (p=0.797).
Conclusion: This study found correlations between the enzyme activity of G6PD and proteinuria as the marker of renal damage in pre-eclampsia (PE) 
with the administration of nifedipine, methyldopa, and magnesium sulfate. However, it had no correlation with isoprostane as the marker of oxidative 
stress. This study suggests that there should be a concern about understanding the pathophysiology of proteinuria for possibility of drug target for 
individuals with PE.
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INTRODUCTION
Preeclampsia is an emergency case in pregnancy due to 
pregnancy-induced hypertension (systolic pressure >140 mmHg, 
diastolic pressure >90 mmHg) which develops after 20 weeks of 
gestation complemented by one or more of the new proteinuria 
onset, maternal organ dysfunction and uteroplacental dysfunction [1]. 
Pre-eclampsia is a major cause of maternal and perinatal morbidity and 
mortality, around 3–10% of all maternal deaths in the world [2]. The 
incidence of preeclampsia (PE) has risen in low socioeconomic status, it 
might be associated with increased prevalence of chronic hypertension, 
obesity, and diabetes [3]. Indonesia as a developing country also 
has pre-diposition of PE. In Dr. Kariadi Hospital, Semarang, Central 
Java, Indonesia, PE incidence was around 2.45% and the main cause 
of maternal death around 40% in 1999 [4]. In Dr. Soetomo Hospital, 
Surabaya, East Java, Indonesia from July 2012 to June 2013, severe 
PE patients were about 461 patients and 24 patients (7%) developed 
into hemolytic elevated liver enzyme low platelet count syndrome 
complication [5].
Preeclampsia is a unique disease in pregnancy and requires crucial 
attention because the etiology and pathophysiology are still 
undetermined. A completely satisfactory and unifying hypothesis has 
not emerged. Schlembach (2003) calls this disease with the disease of 
theories, with one of the causes being oxidative stress [6]. Recent studies 
have investigated the association between PE and G6PD deficiency. 
The result showed that there were incident of G6PD deficiency in PE 
and normal pregnancy although the correlation is not statistically 
significant [7,8]. However, the study also demonstrated that there was 
normal G6PD enzyme activity in PE. Research on G6PD deficiency in PE 
was rarely conducted overseas and none yet in Indonesia.
G6PD enzyme deficiency is an enzyme disorder with the highest 
prevalence, estimated at around 470 million of the entire world 
population in mid-2007 (6,625 billion) (7.09%). The diagnosis of G6PD 
enzyme deficiency occurs when G6PD enzyme activity was <60% which 
will cause clinical signs. Prevalence deficiency of G6PD enzymes in 
Indonesia in men is 5.9% and in women is 3.6%. In this study, there 
were 11 cases (35.5%) of 31 patients with G6PD deficiency and a 
history of poor pregnancy with no known cause [9-12].
Glucose-6-phosphate dehydrogenase (G6PD) enzyme has a role as 
endogenous antioxidant enzymes and a key of enzyme of pentose 
phosphate pathway that forms a part of glycolysis. G6PD is an enzyme 
for producing reduced nicotinamide adenine nucleotide phosphate 
and plays a role as coenzymes and acts by reducing glutathione and 
stabilizing catalase. G6PD deficiency causes increasing production of 
reactive oxygen species (ROS) leading to imbalance between oxidants 
and antioxidants called oxidative stress. Some study hypothesized that 
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there was association between the etiology of PE and stress oxidative 
by ROS [13-15].
Hypertension is tightly associated with progressive kidney 
dysfunction, with manifestation of glomerulosclerosis, interstitial 
fibrosis, proteinuria, and eventually declining glomerular filtration. 
It has been thought that tissue hypoxia induces fibrogenesis and 
progressive renal failure due to the generation of ROS. Renal tissue 
hypoxia decreases renal blood flow, due to high vascular tone induced 
by one of the mechanisms: oxidative stress yielding in increased 
mitochondrial oxygen, tubular electrolyte transport usage, and cutting 
off oxygen from arterial to venous blood in preglomerular vessels. 
Cross-sectional studies on the association between oxidative stress 
markers, isoprostane, and kidney function showed that isoprostane 
increase was commonly found in patients with established chronic 
kidney disease (CKD). Plasma F2-isoprostane, a marker of lipid 
peroxidation, was related to CKD stages and had been increased in 
patients with CKD compared to healthy controls [16,17]. Inhibition 
of angiotensin II (ANG II) activity, by inhibiting the activation of 
angiotensin-converting enzyme and blocking the receptor of ANG II 
type II are important to control hypertension and management with 
antioxidant will improve and protect the kidney tissues. Therefore, it 
seems important to find the possibility drug target for preeclamptic 
patients who have symptoms of kidney disfunction [16,17]. Two ways 
for the management for PE are delivering the fetus (placenta) and 
pharmacological administration with medication of hypertension. 
In Indonesia, pharmacological administration protocol often 
used nifedipine 10–30 mg/day or methyldopa 0.5–3 g/day or and 
intravenous administration of magnesium sulfate or combination. 
Methyldopa decreases norepinephrine (sympathetic outflow) to the 
heart, kidneys, and peripheral vasculature. Methyldopa has better 
result as antihypertension compared to labetalol [18]. Nifedipine is 
a calcium channel blocker mostly used in pregnancy because it can 
significantly drop blood pressure (BP) due to immediate release of oral 
nifedipine. Magnesium sulfate is not an antihypertensive drug but it 
has been used for seizure prevention in PE. The action of magnesium 
sulfate in preventing seizure is not completely unknown; however, 
it is thought to be due to the effect on the central nervous system, 
such as the n-methyl d-aspartate receptors, calcium channels, and 
acetylcholine [19].
METHODS
This cross-sectional study was accomplished in the Muhamad Soewandi 
Hospital, Surabaya, East Java, Indonesia. Total sampling was conducted 
in pregnant women with hypertension and proteinuria. 30 preeclamptic 
women had come to the hospital with the inclusion criteria were 
>20-week gestational age, hypertension, and proteinuria. Pregnant 
women with a history of drug user, malaria, thalassemia, any thyroid 
diseases, and active smokers were excluded from this study. A total 
number of this study were 30 pregnant women of the third trimester 
(>20-week gestational aged) with hypertension and proteinuria. 
Enzyme activity of G6PD was measured by Spectrophotometric method 
using kit of Dialab at wavelength 450 nm. Proteinuria was measured 
by urine dipstick in a commercial clinical laboratory. Isoprostane 
was measured by competitive ELISA method using elabscience kit 
(Cat. No: E-EL-0041) at wavelength 450 nm. Data were expressed 
as mean ± standard deviation. Spearman test was done as a test of 
significance wherever applicable. The statistical analysis was done using 
SPSS version 23. This study had been approved by medical and ethical 
committees of Medical Faculty of Universitas Airlangga, Surabaya, 
Indonesia, with certificate number 215/EC/KEPK/FKUA/2018.
RESULTS AND DISCUSSION
Descriptive data are shown in Table 1. The results of the study 
obtained an average G6PD enzyme activity was 12.68 U/gHb 
(normal reference 4.8–12.5), proteinuria was 1.85 (negative normal 
reference), body mass index (BMI) was 31.07 kg/m2 (reference overweight: 
25–29.9; obesity Grade I: 30–34.9; obesity Grade II: 35–39.9; and obesity 
Grade III: >40), isoprostane level was 11.2 pg/mL, Hb level was 11.2 g/dL 
(normal reference 11.7–15.5), systolic BP was 160.43 mmHg (normal 
<140 mmHg), and diastolic BP was 93.6 mmHg (normal <90 mmHg). 
From these data, it could be indicated that PE patients who had been 
administered by nifedipine, methyldopa, and magnesium sulfate therapy 
had normal G6PD activity with values of proteinuria, BMI, systolic and 
diastolic BP were still above normal values based on reference.
Table 2 shows that there was significant relationship between G6PD 
enzyme activity variables with proteinuria, proteinuria with BP, 
and BP with the occurrence of PE in patients who had been treated 
with nifedipine, methyldopa, and magnesium sulfate. However, there 
was no significant relationship between isoprostane with G6PD 
or proteinuria. From the correlated data, the regression test was 
continued so that the results of causal relationships between variables 
could be found which can be seen in Table 3 and Fig. 1. The results 
showed that the relationship between G6PD enzyme activity and PE 
was hypothesized through variable proteinuria and BP (systolic and 
diastolic). G6PD activity correlates directly with systolic BP, systolic 
BP correlates directly with diastolic BP, and diastolic BP correlates 
directly with PE (Fig. 1).
The aim of this study was to correlate between G6PD enzyme activity, 
proteinuria, isoprostane, and BP in preeclamptic patients with 
nifedipine, methyldopa, and magnesium sulfate therapy. The result 
from this study showed that there was positive correlation between 
G6PD enzyme activity and proteinuria due to the production of ROS 
by hypertension (Table 2). Hypertension is strongly associated with 
increased oxidative stress and reduced PO2 in the kidney, as a result, 
the risk for development of progressive kidney dysfunction will be 
increased. Furthermore, there is increasing evidence that oxidative 
stress contributes to and accelerates hypertension. Other studies 
indicate that BP induces ROS formation dependent on ANG II. ANG II-
induces arterial BP elevation and increases mitochondrial oxidative 
stress [17,20]. However, mitochondrial nitric oxide (NO) production 
increases as O2 is reduced [13], which results in elevated levels of 
ONOO--, the end product reaction between O2 and NO [21,22].
Some studies suggest that in PE patients, there is a large concentration 
of ROS in the placental and maternal circulation, and the antioxidant 
capacity is lower than the normal placenta, which causes oxidative stress. 
ROS production causes impaired remodeling, platelet aggregation, loss 
of vasodilation, inflammation and endothelial dysfunction [13]. One 
of the markers of oxidative stress is measuring the level of membrane 
lipid damage products, isoprostane [23]. Isoprostane is produced by 
the lipid peroxidation process. The result in this study was not showing 
correlation between G6PD enzyme activity with isoprostane [23]. The 
administration of the drug combination nifedipine, methyldopa, and 
Table 1: Mean of G6PD, proteinuria, BMI, isoprostane, hemoglobin, systolic BP and diastolic BP of PE women with nifedipine, 
methyldopa, and magnesium sulfate
G6PD (U/g Hb) Proteinuria (/UL) BMI (kg/m2) Isoprostane (pg/ml) Hb (g/dL) Systolic BP (mmHg) Diastolic BP (mmHg)
12.68 1.85 31.07 651.62 11.2 160.43 93.6
G6PD: Glucose-6-phosphate dehydrogenase, BMI: Body mass index, BP: Blood pressure, PE: Pre-eclampsia
Fig. 1: Regression analysis between significant correlation 
variables
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magnesium sulfate may be thought to have an effect on isoprostane level, 
which successfully controls the BP. High level of BP causes the excessive 
of ROS [16].
Based on the some study, we hypothesized (Fig. 2) that there were 
correlations between G6PD enzyme wih proteinuria and isoprostane. 
G6PD enzyme is an endogenous antioxidant enzymes. This enzyme 
function is reducing the ROS in the cells. If there is a disruption of 
the balance between oxidants and antioxidants, it can cause oxidative 
stress. ROS can enter the placental villi causing oxidative stress in 
placenta. Oxidative stress activates stress signaling (p38α MAPK) and 
then activates the hypoxic transcription factor (1α) so that it will cause 
placental vascularization defects (failure in spiral artery remodeling ) 
and cytotrophoblast only invades the maternal spiral arteries 
superficially. Vascular ischemia produces ROS. The concentration of 
ROS that accumulates from G6PD enzyme deficiency and plasental 
ischemia will enter the systemic circulation, resulting in worsening 
oxidative stress in the cells. Vascular with systemic oxidative stress 
causes disturbance in nitric oxide synthetase (eNOS) mRNA and 
reduced endothelium eNOS transcription so that NO concentrations 
will be low. Low NO concentration results in endothelial dysfunction, 
therefore micro-macroangiopathy will be present in all cells. Renal 
microangiopathy causes impermeable glomerulus so that the protein 
can be detected in the urine. Damage of the walls of blood vessels results 
in high tense of blood vessel tone, increased systolic and diastolic BP 
(hypertension), so that proteinuria and hypertension occur in PE.
Based on the result and some study, it is necessary to give the patients 
pharmacological medicine in preeclamptic patients depends on 
the level of proteinuria and hypertension. Therapeutic target for 
preeclamptic patients focuses on the reduction of hypertension and the 
administration of antioxidant to prevent reduced kidney function.
CONCLUSION
The present study found that there were correlations between the 
enzyme activity of G6PD and proteinuria as a marker of kidney damage 
in preeclamptic patients with nifedipine, methyldopa, and magnesium 
sulfate therapy. This study suggested that there was no association 
between G6PD enzyme activity and isoprostane as a market of stress 
oxidative in preeclamptic patients with nifedipine, methyldopa, and 
magnesium sulfate therapy. However, there is still more possibility to 
do further studies on any drug target for PE by reducing risk factors 
of becoming eclampsia, reducing proteinuria and isoprostane. The 
present study suggests conducting further research by taking samples 
after the use of the drugs in PE.
CONFLICTS OF INTEREST
All authors declared that there were not any conflicts of interest in this 
study.
REFERENCES
1. International society for the study of hypertension in pregnancy, 
pregnancy hypertension : An international journal of women ’s 
cardiovascular health The classification, diagnosis and management 
of the hypertensive disorders of pregnancy : A revised statement from 
the ISSHP. Pregnancy Hypertens. Int J Women’s Cardiovasc Health 
2014;4:97-104.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO 
analysis of causes of maternal death: A systematic review. Lancet 
2006;367:1066-74.
3. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. 
“Pre-eclampsia.” Lancet 2010;376:631-44.
4. Birawa AD, Hadisaputro H, Hadijono S. Kadar d-dimer pada ibu 
hamil dengan preeklampsia berat dan normotensi di RSUP Dr. Kariadi. 
Majalah Obstet. Ginekol Indones 2009;33:65-79.
5. Warih AP, Ernawati E, Susanti D. Characteristic of hellp syndrome in 
severe preeclampsia patients in DR. soetomo hospital Surabaya. Folia 
Medica Indonesiana 2013;51:272-6.
6. Schlembach D. Pre-eclampsia still a disease of theories. Fukushima J 
Med Sci 2003;49:69-115.
7. Popovic J. Glucose-6-phosphate dehydrogenase deficiency and 
pre-eclampsia: Possibility of treatment. Iran J Med Sci 2011;36:324.
8. Asgharnia M, Salamat F, Mirbolook F, Darabian B. Investigating 
the relationship between glucose-6-phosphate dehydrogenase and 
preeclampsia. Iran J Obstet Gynecol Infertil 2013;16:1-7.
Table 2: Statistical analysis; Spearman correlation between 
G6PD, proteinuria, isoprostane, and pre-eclampsia









*Significant. G6PD: Glucose-6-phosphate dehydrogenase, PE: Pre-eclampsia
Table 3: Statistical analysis; regression analysis between 
significant correlation variables
Variable 1 Variable 2 (p) Β
G6PD Proteinuria p=0.0001* 0.534
Proteinuria Systole p=0.019* 0.396
Systole Diastole p=0.0001* 0.665
Diastole PE p=0.037* 0.336
*Significant. G6PD: Glucose-6-phosphate dehydrogenase, PE: Pre-eclampsia
Fig. 2: Hypothesis of the association between glucose-6-
phosphate dehydrogenase and endothelial dysfunction with the 
development of preeclampsia
Int J App Pharm, Vol 11, Special Issue 5, 2019
 Lukitasari et al. 
 4th International Conference on Pharmacy and Pharmaceutical Science (ICPPS) 2019 166
9. Cappelini MC, Fiorelli G. Glucose-6-phosphate dehydrogenase 
deficiency. Lancet 2008;371:64-74.
10. Faruky KS, Begum N, Begum S, Ali T, Ferdousi S, Amin AH. Study 
of glucose-6-phosphate dehydrogenase (G6PD) status in preeclampsia. 
BSMMU J 2009;2:56-60.
11. Kawamoto F, Matsuoka H, Kanbe T, Tantular IS, Pusarawati S, 
Kerong HI, et al. Further investigations of glucose-6-phosphate 
dehydrogenase variants in Flores Island, Eastern Indonesia. J Hum 
Genet 2006;51:952-7.
12. Soemarno TM, Notopuro H, Santoso H. Glucose 6 phosphate 
dehydrogenase (G6PD) deficiency in bad pregnancy history in st. 
Vincentius a paulo catholic hospital, Surabaya. Folia Med Indones 
2007;43:2-7.
13. Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M. 
Endothelial dysfunction and preeclampsia: Role of oxidative stress. 
Front Physiol 2014;5:372.
14. Redman CW, Sargent IL. Circulating microparticles in normal 
pregnancy and pre-eclampsia. Placenta 2008;29 Suppl A: S73-7.
15. Pereira RD, De Long NE, Wang RC, Yazdi FT, Holloway AC, Raha S. 
Angiogenesis in the placenta: The role of reactive oxygen species 
signaling. Biomed Res Int 2015;2015:12.
16. Ravarotto V, Simioni F, Pagnin E, Davis PA, Calò LA. Oxidative stress 
chronic kidney disease cardiovascular disease: A vicious circle. Life Sci 
2018;210:125-31.
17. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, 
Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation 
in patients with moderate to severe chronic kidney disease. Kidney Int 
2004;65:1009-16.
18. Magee LA, CHIPS Study Group, von Dadelszen P, Singer J, Lee T, 
Rey E, et al. Do labetalol and methyldopa have different effects on 
pregnancy outcome? Analysis of data from the control of hypertension 
in pregnancy study (CHIPS) trial. BJOG 2016;123:1143-51.
19. Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. BJOG Int J 
Obstet Gynaecol 2000;107:299-307.
20. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, 
et al. Oxidation of tetrahydrobiopterin leads to uncoupling of 
endothelial cell nitric oxide synthase in hypertension. J Clin Invest 
2003;111:1201-9.
21. Carrière A, Carmona MC, Fernandez Y, Rigoulet M, Wenger RH, 
Pénicaud L, et al. Mitochondrial reactive oxygen species control 
the transcription factor CHOP-10/GADD153 and adipocyte 
differentiation: A mechanism for hypoxia-dependent effect. J Biol 
Chem 2004;279:40462-9.
22. Castello PR, David PS, McClure T, Crook Z, Poyton RO. Mitochondrial 
cytochrome oxidase produces nitric oxide under hypoxic conditions: 
Implications for oxygen sensing and hypoxic signaling in eukaryotes. 
Cell Metab 2006;3:277-87.
23. Wang CN, Chen JY, Sabu S, Chang YL, Chang SD, Kao CC, et al. 
Elevated amniotic fluid F2-isoprostane: A potential predictive marker 
for preeclampsia. Free Radic Biol Med 2011;50:1124-30.
